



BAYAMON MEDICAL CENTER
LABORATORIO DE PATOLOGIA DR. NOY

CARR. #2 KM 11.7, BAYAMON, PR 00960
TEL: (787) 269-6160

DRA. LUZ M. RODRIGUEZ
DIR. MEDICO

Lic. No. 57-B
CLIA No. 40D864526

TISSUE EXAMINATION REPORT

PATIENT NAME:					PATHOLOGY NO:	
TELEPHONE:					RECORD:	
REQUESTING MD:					COLLECTED:	
ROUTE:					RECEIVED:	
HOSP / FACILITY:					REPORTED:	
BIRTH DATE:		AGE:		SEX:		ROOM:

PATHOLOGICAL DIAGNOSIS:

A. STOMACH, MASS, BIOPSY:

- **Tubular adenocarcinoma (intestinal-type), well-differentiated**; see comment.

B. STOMACH, MASS, BIOPSY:

- **Tubular adenocarcinoma (intestinal-type), well-differentiated**; see comment.

- Chronic active gastritis.

Comment: Immunohistochemical studies for mismatch repair (MMR) proteins and HER2 are reported below.
Immunohistochemical stain for PD-L1 will be performed, and addendum report will follow.

Report of immunohistochemical studies:

Block A and B:

H. pylori - negative

These immunohistochemical stains are deemed medically necessary. Concurrent evaluation by IHC on tissue sections is indicated in this case to correlate immunophenotype with cell morphology and determine the extent of involvement, spatial pattern, and focality of potential disease distribution.

Gastric HER2 Biomarker Reporting Template

Applies To: A

GASTRIC HER2 BIOMARKER TESTS

Test(s) Performed:

HER2 by IHC

Results: Positive (Score 3+)

HER2 (protein expression by immunohistochemistry): Food and Drug Administration (FDA) cleared (test / vendor) - ROCHE

Primary Antibody: 4B5

DNA Mismatch Repair Biomarker Testing

Applies To: A

DNA MISMATCH REPAIR TESTING

Immunohistochemistry (IHC) Results for Mismatch Repair (MMR) Proteins:

MLH1 Result: Intact nuclear expression

MSH2 Result: Intact nuclear expression

MSH6 Result: Intact nuclear expression

PMS2 Result: Intact nuclear expression

Mismatch Repair (MMR) Interpretation: No loss of nuclear expression of MMR proteins: No evidence of deficient



TISSUE EXAMINATION REPORT

mismatch repair (low probability of MSI-H)

Microsatellite Instability (MSI) Interpretation: MSI-Stable (MSS)

The presence of MSI-H / deficient mismatch repair may also be an indication for additional testing for Lynch syndrome and genetic counselling.

Heterogeneous expression of MLH1 and PMS2 has been infrequently encountered in endometrial carcinomas (up to 3% of cases). The incidence of heterogeneous expression in other cancer types and its impact on predicting sensitivity to checkpoint inhibition is not currently known.

Addendum (1/22/2026)

Quantitative IHC Biomarker Reporting

Applies To: A

SPECIMEN INFORMATION

Biomarker(s) Assessed:

PD-L1 IHC

PD-L1 IHC Results

Interpretation: Positive

Combined Number of Tumor and Immune Cells with Staining per 100 Tumor Cells (CPS): 2

Comment: See attached consultation report from Fulgent Oncology Laboratories (IHC26-001290)

SPECIMEN:


A. LABELED AS "MASA GASTRICA"

The specimen consists of a light tan, soft tissue biopsy that measures 0.4 x 0.3 x 0.2 cm. (SIT x 1)


B. LABELED AS "MASA GASTRICA"

The specimen consists of light tan, soft tissue biopsies that measure in aggregate 0.5 x 0.3 x 0.2 cm. (SIT x 1) pp/mam

Report Photos



A



HER2

Miguel A. Noy, M.D., F.C.A.P.

ELECTRONIC REMOTE SIGNATURE - RP01

Carlos A. Castrodad, M.D., F.C.A.P.

Gastrointestinal and Liver Pathologist